Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer

Article

Author: Nidhi ; Khan, Imran A. ; Khan, Mohd Ashif ; Reeta ; Garg, Aakriti ; Karhana, Sonali ; Bano, Aysha

Emerging studies have reported the potential anticancer activity of benzimidazole-based anthelmintics (BBA) against lung cancer (LC). However, mechanism underlying the anticancer activity of BBA is unclear. Therefore, in the current study, network pharmacology and molecular docking-based approach were used to explore the potential molecular mechanism for the treatment of LC. The potential targets for BBA were obtained from multiple databases including SwissTargetPrediction, Drug Bank, Therapeutic Target Database, and Comparative Toxicogenomics Database while LC targets were collected from DisGeNet gene discovery platform, Integrated Genomic Database of NSCLC, Catalogue of Somatic Mutations in Cancer and Online Mendelian Inheritance in Man database. Protein-protein interaction (PPI) diagram of common targets was constructed using STRING online platform. Topological analysis was performed using Cytoscape and gene enrichment analysis was conducted using FunRich software. Highest degree targets were then confirmed using molecular docking and molecular dynamics simulations. The BBA were prioritized according to their S scores, with ricobendazole ranking highest followed by flubendazole, fenbendazole, mebendazole, triclabendazole, albendazole, oxibendazole, parbendazole, thiabendazole and oxfendazole. The potential targets of BBA identified using topological analysis and molecular docking were found to be CCND1 (cyclin D1), EGFR (Epidermal Growth Factor Receptor), ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2/CD340), PTGS2 (Prostaglandin-endoperoxide synthase 2), and SRC (Proto-oncogene tyrosine-protein kinase). Furthermore, molecular dynamics confirmed that CCND1 and EGFR are the potential targets of ricobendazole for the treatment of LC. BBA can be further explored as a therapeutic strategy for the treatment of lung cancer under in vitro and in vivo studies.Communicated by Ramaswamy H. Sarma.

14 Nov 2024·The Korean Journal of Physiology & Pharmacology

Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells

Article

Author: Du, Zhuanyun ; Zhang, Wenyao ; Feng, Wenli ; Yang, Li ; Yuan, Ying ; Peng, Yuhang

To target the pivotal BCR/ABL oncoprotein in chronic myeloid leukemia (CML) cells, tyrosine kinase inhibitors (TKIs) are utilized as landmark achievements in CML therapy. However, TKI resistance and intolerance remain principal obstacles in the treatment of CML patients. In recent years, drug repositioning provided alternative and promising perspectives apart from the classical cancer therapies, and promoted anthelmintic mebendazole (MBZ) as an effective anti-cancer drug in various cancers. Here, we investigated the role of MBZ in CML treatment including imatinib-resistant CML cells. Our results proved that MBZ inhibited the proliferation and induced apoptosis in CML cells. We found that MBZ effectively suppressed BCR/ABL kinase activity and MEK/ERK signaling pathway by reducing p-BCR/ABL and p-ERK levels with ABL1 targeting ability. Meanwhile, MBZ directly targeted the colchicine-binding site of β-tubulin protein, hampered microtubule polymerization and induced mitosis arrest and mitotic catastrophe. In addition, MBZ increased DNA damage levels and hampered the accumulation of ataxia-telangiectasia mutated and DNA-dependent protein kinase into the nucleus. This work discovered that anthelmintic MBZ exerts remarkable anticancer effects in both imatinib-sensitive and imatinib-resistant CML cells in vitro and revealed mechanisms underlying. From the perspective of drug repositioning and multi-target therapeutic strategy, this study provides a promising option for CML treatment, especially in TKI-resistant or intolerant individuals.

01 Nov 2024·Journal of Chromatography A

Online restricted access molecularly imprinted solid phase extraction coupled with electrospray ionization-tandem mass spectrometry for determination of mebendazole and albendazole in milk samples

Article

Author: Bonfilio, Rudy ; Lourêdo, Amanda Aparecida Marques ; Santos, Mariane Gonçalves ; Pereira, Helton Hanchuck

Multifunctional materials, such as restricted access molecularly imprinted polymers covered with bovine serum albumin (RAMIP-BSA), are effective alternatives for sample preparation techniques. This material selectively adsorbs analytes while excluding macromolecules, enhancing the analysis's efficiency. Among analytical techniques, ESI-MS/MS (Electrospray Ionization-Tandem Mass Spectrometry) has successfully identified and quantified various molecules, including trace-level drugs. Therefore, we proposed, for the first time, an integrated online extraction/analysis system that combines the benefits of RAMIP-BSA and ESI-MS/MS for analyzing mebendazole (MBZ) and albendazole (ABZ) in milk samples without the need for chromatographic separation. Initially, a RAMIP selective for MBZ was synthesized using the bulk method with methacrylic acid and glycidyl methacrylate. Then, the polymer was covered with bovine serum albumin. Subsequently, this adsorbent was packed in a small column and coupled with an ESI-MS/MS instrument in an online configuration. Milli-Q water was used as the loading and reconditioning mobile phases, and a solution of formic acid in methanol (1:100 v/v) was employed as the elution phase. The system enabled simultaneous extraction and determination of MBZ and ABZ in milk samples. The method exhibited linearity between 15.0 and 125.0 μg L^-1 for MBZ and 10.0 and 125.0 μg L^-1 for ABZ (with a correlation coefficient exceeding 0.99). The limits of quantification were 15.0 and 10.0 μg L^-1 for MBZ and ABZ, respectively. Good precision and accuracy were achieved. The developed method was used to analyze MBZ and ABZ in real milk samples and proved to be a viable alternative to conventional sample preparation and chromatographic techniques.

News (Medical) associated with Mebendazole

14 Feb 2024

·www.sciencedaily.com

Controlling root growth direction could help save crops and mitigate climate change

Scientists have determined how the well-known plant hormone ethylene is crucial in controlling the angle at which roots grow. The findings can be used to engineer plants and crops that withstand the environmental stresses of climate change and drought, and perhaps to create plants that remove carbon dioxide from the atmosphere and store it deep underground to help mitigate climate change. Above ground, plants stretch toward the sun. Below ground, plants tunnel through the earth. As roots soak up water and nutrients from surrounding soil, they grow and stretch to develop distinct root system architectures. The root system architecture determines whether roots remain in the shallow soil layers or grow steeper and reach deeper soil layers. Root systems are central to plant survival and productivity, determining the plant's access to nutrients and water and, therefore, the plant's ability to withstand nutrient depletion and extreme weather like drought. Now, Salk scientists have determined how a well-known plant hormone is crucial in controlling the angle at which roots grow. The study, published in Cell Reports on February 13, 2024, is the first time the hormone, called ethylene, has been shown to be involved in regulating lateral root angles that shape root systems -- making the findings a revelation for plant scientists optimizing root systems. Researchers in Salk's Harnessing Plants Initiative now plan to target the ethylene signaling pathway in their efforts to engineer plants and crops that can withstand the environmental stresses of climate change and drought, as well as removecarbon dioxide from the atmosphere and store it deep underground to help mitigate climate change. "Deep roots lead to more durable carbon storage in the soil and can make plants more resistant to drought, so the ability to control how deep roots grow is really exciting for scientists looking to engineer better root systems," says senior author Wolfgang Busch, professor, executive director of the Harnessing Plants Initiative, and Hess Chair in Plant Science at Salk. "We're especially excited that the pathway we found is conserved across many types of plants, meaning our findings can be widely applied to optimize root architecture in all land plants, including food, feed, and fuel crops." Environmental factors -- like average rainfall or abundance of certain nutrients -- can influence the shape of a plant's root system. The angle at which roots grow produces different results in overall root architecture, with horizontal root angles creating a shallower root system and vertical root angles creating a deeper root system. But scientists did not understand clearly how these root angles were being determined on a molecular level. Plant hormones like auxin and cytokinin have been connected to the angle of root growth in the past, but the mechanisms of that connection have remained poorly understood. In searching for molecules and pathways that were involved in setting the angle of root growth, the team genetically screened Arabidopsis thaliana -- a small flowering weed in the mustard family -- for root system changes in response to thousands of molecules. "We noticed this molecule called mebendazole was causing the roots to grow more horizontally," says first author Wenrong He, a former postdoctoral researcher in Busch's lab. "When we looked for what target proteins or pathways mebendazole was interacting with to have this effect, we discovered it was ethylene signaling -- and ethylene playing such an essential role in root system architecture was really intriguing." The team observed that genes throughout the ethylene signaling pathway were activated in response to mebendazole, and, in turn, the pathway was carrying out the resulting changes in root growth. Biochemical investigation of this relationship revealed that mebendazole inhibits the activity of a protein kinase called CTR1. This enzyme negatively regulates ethylene signaling, in turn promoting a shallow root system. "Since ethylene signaling is a widely conserved process in land plants, targeting the ethylene pathway is a very promising technique for root system engineering," says Busch. "Hopefully, now we'll be able to use this tool to make crop species more resilient, and to create Salk Ideal Plants® that sequester more carbon underground to assist in the fight against climate change." The newfound implication of ethylene in root system architecture inspires new questions, including whether another molecule exists that -- unlike mebendazole -- makes root systems deeper, or if there are specific genes in the already well-cataloged ethylene signaling pathway that can be targeted most effectively to promote deeper roots in crops and Salk Ideal Plants. Other authors include Hai An Truong, Ling Zhang, Min Cao, and Kaizhen Zhong of Salk; Neal Arakawa of UC San Diego; Yao Xiao of the Scripps Research Institute; and Yingnan Hou of UC Riverside and Shanghai Jiao Tong University in China. The work was supported by Salk's Harnessing Plants Initiative, a Salk Women & Science Special Award, a Pioneer Fund Postdoctoral Scholar Award, the National Institutes of Health (NIH-NCI CCSG: P30 CA01495, NIH-NIA San Diego Nathan Shock Center P30 AG068635), Chapman Foundation, and Helmsley Charitable Trust.

20 Oct 2023

·www.jnj.com

Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model

Chicago, Illinois (October 20, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today promising data from a Phase 2a human challenge study evaluating JNJ-1802, a first-in-class oral antiviral in development for the prevention of dengue. The data showed that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo, and is safe and well-tolerated. The data were announced at the American Society of Tropical Medicine & Hygiene Annual Meeting in Chicago, Illinois.JNJ-1802 is the first antiviral to show such activity in humans during a clinical trial. The compound has advanced to a community-based field study to establish efficacy against circulating dengue serotypes in a real-world setting. The study is being conducted in 30+ sites in 10 countries, including Philippines, Thailand, Peru, Brazil and Colombia.“Climate change threatens to put more people at risk of dengue, yet the world lacks the necessary tools to combat this significant health challenge,” said Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D at Janssen Research & Development, LLC. “For over a decade, we have been committed to following the science to bring forward new solutions for dengue and this new data is an encouraging step forward to addressing the expanding impact of climate change on human health.”The two-center, randomized, double-blind, placebo-controlled human challenge study evaluated the antiviral activity, safety and pharmacokinetics of different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults. All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5. All participants were monitored over 85 days. The study found dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.“The promising results of JNJ-1802 to date offer the hope that science will be able to deliver against this threat as more and more communities are impacted worldwide,” said Marnix Van Loock, Ph.D., Lead for Emerging Pathogens, Global Public Health R&D at Janssen Pharmaceutica NV. “Dengue requires global action, and we are proud to collaborate alongside partners around the world in advancing the development of this compound to its next phase.”This study follows data published in Nature in March 2023, which showed that JNJ-1802 provides strong protection against dengue in non-human primates and mice, and a Phase 1 first-in-human clinical study showing that the antiviral was safe and well-tolerated.Janssen thanks its supporting partners including the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Clinical Research (DCR and Office of Clinical Research Policy and Regulatory Operations (OCRPRO) for their collaboration in conducting this trial.A New Tool to Fight a Growing ThreatThe development of a dengue antiviral is critically important to global health. Over half the world’s population currently lives in areas where dengue is endemic. Dengue fever impacts at least 400 million annually, sickening an estimated 100 million and killing thousands, with more going undiagnosed or misdiagnosed.Changes in climate are exacerbating the crisis, lengthening the infection season and allowing the mosquito that carries the virus to spread beyond its native regions. In 2023, countries like Bolivia, Peru and Bangladesh have already reported some of their worst outbreaks on record, and countries like the U.S., Spain and France are seeing a rise of locally acquired cases for the first time.Research and development (R&D) against dengue has proven challenging due to four globally circulating serotypes and there are currently no therapeutics and only two licensed vaccines limitedly available. Investment in antivirals, which do not require cold chain and can induce immunity in just days, is sorely needed to diversify the prevention toolbox to slow down outbreaks and limit epidemic-levels of cases.Johnson & Johnson’s Commitment to DengueJohnson & Johnson has been investing in dengue R&D for over a decade. The Company is also collaborating closely with academic partners to bolster local R&D. In June 2022, Johnson & Johnson launched its Satellite Center for Global Health Discovery at Duke-NUS in Singapore, which is focused on accelerating early-stage discovery research to address the growing challenge of flaviviruses, including dengue.These efforts are part of Johnson & Johnson’s more than 15-year legacy working to address the burden of neglected tropical diseases (NTDs), a group of about 20 communicable diseases that together affect more than 1.7 billion people in 149 countries around the world. In 2022, the Company joined the global community to endorse the Kigali Declaration on Neglected Tropical Diseases, pledging to continue to donate up to 200 million doses annually of mebendazole through 2025 to tackle intestinal worms and advance novel R&D programs to discover new medications needed to beat leprosy and dengue.You can learn more about our efforts to beat NTDs, including dengue, by visiting JNJ.com/NTDs.  About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.Learn more at www.janssen.com. Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/. Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding dengue fever, flavivirus and neglected tropical diseases. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Pharmaceutica NV and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Pharmaceutica NV nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Phase 2VaccineClinical ResultPhase 1

27 Jun 2023

·www.prnewswire.com

Animal Parasiticides Global Market is Projected to Reach $14.1 Billion by 2030: Rising Prevalence of Zoonotic Disorders Spark Demand for Animal Parasiticides

DUBLIN, June 27, 2023 /PRNewswire/ -- The "Animal Parasiticides: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Animal Parasiticides estimated at US$9.5 Billion in the year 2022, is projected to reach a revised size of US$14.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2022-2030. Ectoparasiticides, one of the segments analyzed in the report, is projected to record a 5.6% CAGR and reach US$5.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Endoparasiticides segment is readjusted to a revised 5% CAGR for the next 8-year period. The U.S. Market is Estimated at $2.2 Billion, While China is Forecast to Grow at 6.9% CAGR The Animal Parasiticides market in the U.S. is estimated at US$2.2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 5.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.7 Billion by the year 2030. Select Competitors (Total 30 Featured) - Bayer AG Boehringer Ingelheim International GmbH Ceva Sante Animale Elanco Animal Health Merck Animal Health PetIQ Vetoquinol SA Virbac SA Zoetis, Inc. Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Veterinary Parasiticides: An Introduction General Characteristics of Animal Parasiticides Most Common Chemical Classes of Veterinary Parasiticides: An Overview Classification of Ectoparasiticides Different Delivery Forms of Ectoparasiticides Classification of Endoparasiticides Different Delivery Forms of Anthelmintics An Insight into Formulations of Veterinary Parasiticides Proportion of Non-Active Ingredients in Different Antiparasitic Product Formulations Original and Generic Antiparasitics Original Antiparasitics Generic Antiparasitics Animal Parasiticides: Vital for the Treatment of Parasitic Diseases in Animals Animal Parasiticides Market to Witness Healthy Growth Ectoparasiticides: The Largest Product Segment Food-Producing Animals: The Major End-Use Segment for Animal Parasiticides Developed Regions Lead the Global Animal Parasiticide Market Animal Parasiticides - Global Key Competitors Percentage Market Share in 2022 (E) Ectoparasiticides (Product) Global Competitor Market Share Positioning for 2019 & 2025 Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Growing Awareness about Animal Healthcare and Increased Spending on Animal Healthcare Products and Medication Augurs and Well for Animal Parasiticides Market Animal Healthcare Market Worldwide: Revenues in US$ Billion for the Years 2018, 2020, 2022 and 2024 Rising Prevalence of Zoonotic Disorders Spark Demand for Animal Parasiticides Rising Adoption of Pets and Companion Animals Fuels Demand for Animal Parasiticides Pet Population Worldwide: Number of Dogs and Cats in Million for the Years 2017 and 2018 Global Pet Dog Population: Number of Pet Dogs by Select Countries in Million for the Year 2018 Global Pet Cat Population (2018): Number of Pet Cats by Select Countries in Million for the Year 2018 With Demand for Protein Rich, Animal-Derived Foods Continuing to Grow, Parasiticides Market is Poised for Growth World Population (in Thousands) by Geographic Region for the Years 2018, 2025, 2040, 2050 Per Capita Meat Consumption in Kg/Per Person/Year by Region by Meat Type for 2015-2017 Global Protein Consumption: Breakdown of Meat Consumption in 1,000 Metric Tons (Carcass Weight Equivalent) for the Years 2015-2019 Sustained Increase in Number of Veterinary Practitioners in Developed Regions Drives Sales of Parasiticides Number of Veterinarians in the US by Gender for the Years 2016, 2017 and 2018 Trend towards Vegetarian Diet Hampers Market Growth Countries with Highest Proportion of Vegetarian Diet: Vegetarianism as % of Total Population for the Year 2018 Regulations Restricting Use of Parasiticides for Food-Producing Animals Impedes Demand Growth Developing Oral Forms of Ectoparasiticides: An Area of Focus for Market Players Resistance to Antiparasitics in Animals: A Major Concern 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Mebendazole

External Link

KEGG	Wiki	ATC	Drug Bank
D00368	Mebendazole	P02CA01	DB00643

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Trichuriasis	JP	Janssen Pharmaceutical KK	29 Mar 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Helminthiasis	Phase 3	RW	Janssen Research & Development LLC	01 Dec 2014
Helminthiasis	Phase 3	ET	Janssen Research & Development LLC	01 Dec 2014
Parasitic Diseases	Phase 3	TZ	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Feb 2010
Anemia	Phase 3	PK	Johns Hopkins Bloomberg School of Public Health	01 Apr 2004
Brain Stem Glioma	Phase 2	US	Janssen Pharmaceuticals, Inc.	22 Oct 2013
Glioblastoma Multiforme	Phase 2	US	Janssen Pharmaceuticals, Inc.	22 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTRI/2018/01/011542 (BELOB, ASCO2022) Manual	Phase 2	Recurrent Glioblastoma	-	lomustine+Mebendazole	(rvhedkfiyu) = priforloey xdfwlvhjux (hnceticrow, 29.6 - 59.2) View more	Negative	02 Jun 2022
				temozolomide+Mebendazole	(rvhedkfiyu) = rsjoqvzezc xdfwlvhjux (hnceticrow, 22.3 - 51) View more
NCT03925662 (Pubmed \| Life Sci) Manual	Phase 3	Metastatic Colorectal Carcinoma	40	Mebendazole + bevacizumab + FOLFOX4	tmytwkpvhu(cjdkkmitdi): P-Value = 0.063 View more	Positive	03 Apr 2022
				Bevacizumab + FOLFOX4 + placebo
NCT03995680 (CHEW_MEB_PEMBA, CTgov)	Phase 2	Hookworm Infections	397	Mebendazole (Chewable Tablet of Mebendazole)	iknculicgp(pvjccgguhv) = ffqwauthbl qinwalovhe (bilxizfgdc, rtileuftlh - ysrgifekrb) View more	-	20 Jul 2020
				Mebendazole (Swallowable Tablet of Mebendazole)	iknculicgp(pvjccgguhv) = zvezuucfhk qinwalovhe (bilxizfgdc, egwjicmyxe - mjwccqxczj) View more
NCT03245398 (CTgov)	Phase 4	Hookworm Infections	186	one of the two regimens of mebendazole (Single Dose of Mebendazole)	vcdgpidtsc(vqsvqemsqc) = zeubzqowdo jcycixvckx (lfhqtpwzve, rrkvvxmzph - nfbzalstck)	-	17 Jun 2019
				one of the two regimens of mebendazole (Multiple Dose of Mebendazole)	vcdgpidtsc(vqsvqemsqc) = aomdmalamt jcycixvckx (lfhqtpwzve, rrxlbgktsg - bdwwfxhgyy)
NCT03245398 (Pubmed) Manual	Phase 4	Hookworm Infections	185	Single dose mebendazole	(elvbxasllw) = xnbuniegua rculhdiwxl (wlixqtbafa ) View more	Positive	01 Jul 2018
				Multiple dose mebendazole	(elvbxasllw) = mbtqcaoqlg rculhdiwxl (wlixqtbafa ) View more
NCT02034162 (CTgov)	Phase 3	Helminthiasis	295	placebo (Double-blind Placebo)	uaxuwwquab(vhvxzsvfra) = cbyopxspnz fcijwwxftr (grwralkapr, frwzuifmcf - yklzfopgkv) View more	-	04 Nov 2016
				Mebendazole (Double-blind Mebendazole 500 mg)	uaxuwwquab(vhvxzsvfra) = fvlepvhdsf fcijwwxftr (grwralkapr, nqlexnlvlk - ittdjijqlr) View more
NCT01379326 \| NCT01087099 (Pubmed \| PLoS Negl Trop Dis) Manual	Phase 4	Helminthiasis	250	Mebendazole 500 mg	(ljrpfjdhkb) = tvircznigf juyhoelzvc (llvozajbbe, 95.8 - 99.5) View more	Positive	01 Oct 2014
				Albendazole 400 mg	(ljrpfjdhkb) = rpwozbxlku juyhoelzvc (llvozajbbe, 99.0 - 100) View more
NCT01350271 (CTgov)	Phase 3	Helminthiasis	214	Placebo (Placebo)	utwmandrnc(acxtpeucmw) = ejsnlieshg zhfiqkzacv (fijgxnvzfh, udpirbrkou - nmgluzrszw) View more	-	22 Apr 2013
				Mebendazole polymorph A (Mebendazole Polymorph A and C 500 mg)	utwmandrnc(acxtpeucmw) = hiqgsgzutk zhfiqkzacv (fijgxnvzfh, fvldvnwsxa - glaowiyvoa) View more
ERS2012 Manual	Not Applicable	Persistent asthma total IgE \| Ascaris-specific IgE	24	Mebendazole	wugqifoqnp(ecykqstgit) = xvwtwgrshe ehlozuhslp (pdrphcgbrl ) View more	Positive	01 Sep 2012
ISRCTN29126001 (Pubmed)	Not Applicable	Helminthiasis \| Hookworm Infections	200	Albendazole	(lsdjztyecc) = xqgkceptav kldwqgjefd (uizlroeyng ) View more	-	01 Jan 2012
				Mebendazole	(lsdjztyecc) = twntxupogu kldwqgjefd (uizlroeyng ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis